Sjogren's syndrome: Review of the aetiology, Pathophysiology & Potential therapeutic interventions
- PMID: 28469828
- PMCID: PMC5410683
- DOI: 10.4317/jced.53605
Sjogren's syndrome: Review of the aetiology, Pathophysiology & Potential therapeutic interventions
Abstract
Background: Sjogren's syndrome (SS) is an autoimmune disorder characterised by lymphocytic infiltration of exocrine glands, resulting in glandular dysfunction. Objectives: This study aims to review the aetiology of Sjogren's syndrome, highlight aspects that contribute to the pathophysiology of the disease and explore treatment options that target different mediators of pathogenesis.
Material and methods: The MEDLINE/PubMed and Google Scholar databases were searched systematically with the terms "Sjogren's syndrome"; "clinical"; "treatment"; "management". Eligible studies had to meet a predefined inclusion criteria.
Results: 912 identified studies were evaluated against the inclusion criteria. 25 eligible studies were included for review. Sjogren's syndrome is a multifactorial condition with genetic, environmental and hormonal factors playing a role in establishing the condition. B-cell activating factor (BAFF) is an important mediator in the induction and perpetuation of this condition. Elevated BAFF levels, found in patients with SS, promote growth of B-cells and subsequent production of autoantibody; anti-SSA/Ro. BAFF inhibitors are important potential therapeutic drugs that may be effective in patients with Sjogren's syndrome. Other potential targets include CD20 and CD22 that cause B-cell depletion.
Conclusions: The pathophysiology of this exocrinopathy has not fully been elucidated. Potential therapeutic interventions include BAFF inhibitors and anti-CD20 and anti-CD22 therapy. However, no clinical trials have been conducted on subjects with Sjogren's syndrome to support existing research. Key words:Sjogren's syndrome, autoimmune, rheumatology.
Conflict of interest statement
Conflict of interest statement:The authors hereby report no conflicts of interest with regards to this work.
Similar articles
-
Pathophysiology of Sjögren's syndrome.Arch Med Res. 2006 Nov;37(8):921-32. doi: 10.1016/j.arcmed.2006.08.002. Arch Med Res. 2006. PMID: 17045106 Review.
-
Are the B cells cast with the leading part in the Sjogren's syndrome scenario?Oral Dis. 2014 Sep;20(6):529-37. doi: 10.1111/odi.12153. Epub 2013 Jul 10. Oral Dis. 2014. PMID: 23837848 Review.
-
[Sjögren's syndrome (SS), a review of the subject and saliva as a diagnostic method].Gac Med Mex. 2016 May-Jun;152(3):371-80. Gac Med Mex. 2016. PMID: 27335194 Review. Spanish.
-
Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren's syndrome: data from a nationwide cohort for Sjögren's syndrome in Korea.Clin Exp Rheumatol. 2019 May-Jun;37 Suppl 118(3):107-113. Epub 2019 Jul 22. Clin Exp Rheumatol. 2019. PMID: 31376264
-
Advances in the Aetiophatogenesis of Sjögren's Syndrome: a Literature Review.J Oral Maxillofac Res. 2012 Apr 1;3(1):e2. doi: 10.5037/jomr.2012.3102. J Oral Maxillofac Res. 2012. PMID: 24422004 Free PMC article. Review.
Cited by
-
Identification of Sjögren's syndrome patient subgroups by clustering of labial salivary gland DNA methylation profiles.PLoS One. 2023 Mar 2;18(3):e0281891. doi: 10.1371/journal.pone.0281891. eCollection 2023. PLoS One. 2023. PMID: 36862625 Free PMC article.
-
Salivary and Lacrimal Gland Alterations of the Epidermal Fatty Acid-Binding Protein (E-FABP) in Non-Obese Diabetic Mice.Int J Mol Sci. 2022 Mar 23;23(7):3491. doi: 10.3390/ijms23073491. Int J Mol Sci. 2022. PMID: 35408851 Free PMC article.
-
MicroRNA in Sjögren's Syndrome: Their Potential Roles in Pathogenesis and Diagnosis.J Immunol Res. 2018 Jun 7;2018:7510174. doi: 10.1155/2018/7510174. eCollection 2018. J Immunol Res. 2018. PMID: 29977932 Free PMC article. Review.
-
The potential relationship between Flammer and Sjögren syndromes: the chime of dysfunction.EPMA J. 2017 Aug 14;8(4):333-338. doi: 10.1007/s13167-017-0107-5. eCollection 2017 Dec. EPMA J. 2017. PMID: 29209436 Free PMC article. Review.
-
Musculoskeletal Manifestations in Sjogren's Syndrome: An Orthopedic Point of View.J Clin Med. 2021 Apr 8;10(8):1574. doi: 10.3390/jcm10081574. J Clin Med. 2021. PMID: 33917955 Free PMC article. Review.
References
-
- Borchers AT, Naguwa SM, Keen CL, Gershwin ME. Immunopathogenesis of Sjogren's syndrome. Clin Rev Allergy Immunol. 2003;25:89–104. - PubMed
-
- Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjogren's syndrome. Arthritis Rheum. 2000;43:1647–54. - PubMed
-
- Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology (Oxford) 2006;45:iii3–4. - PubMed
-
- Harley J, Scofield R, Reichlin M. Anti-Ro in Sjogren's syndrome and systemic lupus erythematosus. Rheumatic diseases clinics of North America. 1992;18:337–58. - PubMed
-
- Shearn MA. Sjögren's syndrome in association with scleroderma. Annals of internal medicine. 1960;52:1352–62. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials